<DOC>
	<DOCNO>NCT01577355</DOCNO>
	<brief_summary>This single dose study radiolabelled LY2784544 healthy male subject study absorption , distribution , metabolism excretion LY2784544 . This study research purpose intend treat medical condition .</brief_summary>
	<brief_title>A Study LY2784544 Healthy Male Subjects</brief_title>
	<detailed_description>This study approximately 10 day long , ( minimum 5 day , maximum 15 day ) include screen follow . Screening require within 28 day prior first dose study drug follow require least 7 day discharge clinical research unit .</detailed_description>
	<criteria>Overtly healthy male determine medical history physical examination Will either sterile , sexually active , agree use reliable method birth control day dose 3 month end study Have body mass index ( BMI ) 19 29 kg/m^2 , inclusive Have clinical laboratory test result within normal reference range Clinical Research Unit ( CRU ) result acceptable deviation judge clinically significant investigator Normal blood pressure ( BP ) heart rate ( sit ) determine investigator Have venous access sufficient allow blood sample per study requirement Are reliable willing make available duration study willing abide CRU policy procedures study restriction Have give write informed consent approve Lilly institutional review board ( IRB ) govern CRU Are currently enrol , complete , discontinue within last 30 day clinical study involve investigational product concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2784544 relate compound Have previously complete withdrawn study study investigate LY2784544 Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history evidence significant active neuropsychiatric disease particular evidence significant medical psychiatric illness within past 12 month suicidal risk time screen opinion investigator Have condition opinion investigator would preclude participation study Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Use herbal preparation contain St. John 's Wort , kava , garlic , ginger , gingko biloba , guarana within 14 day prior admission time study Intent use overthecounter ( OTC ) medication prescription medication within 7 day prior dose time study Consumption grapefruit grapefruitcontaining food grapefruitcontaining juice , Seville oranges Seville orange juice , star fruit star fruit juice within 7 day prior dose time study Have average weekly alcohol intake exceed 21 unit per week unwilling stop alcohol consumption duration study Have donate blood 500 mL within last month Have participate [ 14C ] study within last 6 month prior admission study . The total exposure study previous study must within Code Federal Regulations ( CFR ) recommend level consider safe ( per 21 CFR 361.1 ) , less 5000 millirems ( mrem ) /year whole body annual exposure Exposure significant radiation within 12 month prior dose ( example , serial Xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) Are currently smoker user tobacco nicotinereplacement product within 6 month prior study entry Baseline 12lead electrocardiogram ( ECG ) correct QT ( Bazett 's ) interval &gt; 450 msec and/or abnormality 12lead ECG , opinion investigator , increase risk associate participate study Regularly use know drug abuse and/or show positive finding urinary drug screen Have history congestive heart failure , unstable angina , myocardial infarction , document history ventricular arrhythmia Gastrointestinal disorder cause clinically significant symptom nausea , vomit , diarrhea , malabsorption syndrome Evidence active renal disease ( e.g. , diabetic renal disease , polycystic kidney disease ) creatinine clearance ( CrCl ) less 70 mL/min Urinalysis ≥1+ protein ≥1+ blood ( unless attributable acute condition resolve prior dose ) Use drug narrow therapeutic window also know substrates Cytochrome P450 ( CYP ) 1A2 , CYP2B6 , CYP3A specifically exclude Use antacid proton pump inhibitor Typically produce least one bowel movement per day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>